Could targeted drugs spare brain cancer patients from radiation after surgery?

NCT ID NCT07655583

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study explores whether people with melanoma or non-small cell lung cancer that has spread to the brain can safely skip stereotactic radiosurgery (focused radiation) after having a brain tumor surgically removed. Instead of radiation, participants receive systemic therapy tailored to their cancer type—such as immune checkpoint inhibitors for melanoma or targeted pills for certain lung cancers. The goal is to see if these drugs alone can prevent the tumor from coming back at the surgical site, potentially avoiding the side effects of radiation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

systemic therapy (immune checkpoint inhibitors for melanoma; osimertinib for EGFR-mutant NSCLC; brigatinib, alectinib, or lorlatinib for ALK-positive NSCLC)

What this could lead to

If successful, this approach could allow some patients to avoid brain radiation after surgery, relying instead on targeted drugs or immunotherapy to prevent recurrence.

What could go wrong

This is a very small pilot study with only 20 participants, so results may not apply broadly. The cancer could still return in the brain without radiation, and the drugs have their own side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm in the brain metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States